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Sir,
With reference to the study by Ward et al (2006), the article
compares the cost effectiveness of oral fluoropyrimidine treatment
for mCRC vs intravenously administered therapies. In particular,
this paper compares Uftoral
s (tegafur–uracil), with capecitabine,
based on unit costs for drugs as outlined in the British National
Formulary, 2002. However, there are a number of discrepancies we
would like to highlight with this assessment. First, as of March
2006 the price of Uftoral
s (tegafur–uracil) was reduced as
indicated in the following table:
Given this significant change in price, over a standard three
cycles of treatment (105 days), the new price represents a 59%
reduction in drug costs (including costs of folinic acid). If the cost
minimisation assessment as completed by Ward et al is replicated
and we include the new NHS price for Uftoral
s, the treatment
costs for a 12-week course of tegafur with uracil would be d1788.
This is lower than any of the other therapies referred to in the
article and represents a cost saving vs capecitabine of d343.1 over a
12-week period.
We believe that there are also inaccuracies in the estimation of
costs related to adverse events included within the model. In table
5, Ward et al report the frequency of consultations and
hospitalisations relating to adverse events over the treatment
period for capecitabine, UFT/LV (Uftoral
s) and the Mayo
regimens. The sources referenced for UFT/LV are Roche (2002)
and Pazdur et al (1999). In assessing Pazdur et al (1999),
information as included in table 5 of Ward et al, is not reported
in this publication. Additionally, we believe the reference, ‘Roche
(2002) ‘Xeloda (capecitabine): achieving clinical excellence in the
treatment of metastatic colorectal cancer. Roche submission to the
National Institute of Clinical Excellence’, to be either incorrect or
inappropriate as this source cannot be referenced. Therefore, we
question whether the stated figures for UFT/LV for, ‘A and E’,
‘Clinic Consultation’ and ‘Other hospital visits’ are appropriate for
inclusion in such an analysis. We also dispute why these categories
would have a zero frequency of incidence for patients treated with
capecitabine, yet be an issue with UFT/LV.
Finally, we would also dispute how the adverse event costs for
Uftoral
s are assumed to be equal to that of the Mayo regimen. We
believe that this is an overestimation and biased against Uftoral
s.
We would propose that adverse event costs for Uftoral
s are more
likely to be lower or at least equal to capecitabine, given the
incidence of hand and foot syndrome as a prominent adverse event
for capecitabine.
Given the points raised, the article by Ward et al, misrepresents
the current costs of treating metastatic colorectal cancer with
Uftoral
s and this could result in clinicians being less willing to
include Uftoral
s in their treatment protocols.
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